Pre-made Motavizumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-357-1mg	1mg	3090
GMP-Bios-ab-357-10mg	10mg	Inquiry
GMP-Bios-ab-357-100mg	100mg	Inquiry
GMP-Bios-ab-357-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Motavizumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody
INN Name	Motavizumab
Target	RSV gpF
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	3qwo:AB:HL/3ixt:HL:AB/4zyp:NO:JL:KM/6oe5:BC
99% SI Structure	5k8a:BA:FE:VM:HL/4jlr:AB:HL
95-98% SI Structure	None
Year Proposed	2006
Year Recommended	2007
Companies	MedImmune
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Respiratory syncytial virus infections
Development Tech	Affinity Matured from Palivizumab